Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a
            <i>RCSD1::ABL2</i>
            fusion gene

Zahid, Mohammad Faizan; Kainthla, Radhika

doi:10.1080/10428194.2023.2264428

Leukemia & Lymphoma

2023

DOI: 10.1080/10428194.2023.2264428

|View full text |Cite

Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Mohammad Faizan Zahid,

Radhika Kainthla

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Cited by 3 publications

References 16 publications

Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene

Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene

Antineoplastics

SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About